Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis (M. tuberculosis), is one of the deadliest diseases ever known to human being. It is expected that a quarter of the world population is living/infected with latent or active for TB or catches during their lifetime, leading to the declaration of TB as a global health concern (Pai, 2018). The strains of M. tuberculosis have been known to invade several parts of the body, including lungs (most common target), skeletal system, lymphatic system, urinary systems etc. In fact, M. tuberculosis has the potential to affect all organs in the body using body's own circulatory system. Therefore, not only it is hugely devastating to human population, but also shattering to the economy of a nation. For instance, the worldwide costs of TB control is more than $4.2 billion, which is much less than the available fund (Jassal & Bishai, 2010). A significant portion of patients comes from both the under- developed and developing nations especially Asian countries (Okamori et al., 2018). Despite the fact that a sharp decrease in the number of TB patient was reported in the beginning of 21st century, sudden onset in resistant cases worsen the situation worldwide (Lönnroth, Jaramillo, Williams, Dye, & Raviglione, 2009). In addition, lengthy and complex treatment regimens, lack of availability of resistant TB drugs, co-infection of HIV, drug toxicities and drug-drug interactions further worsen the situation (Croft, Sundar, & Fairlamb, 2006). Fortunately, an enormous progress has been made and several antitubercular drugs have been developed to curb this menace (Alffenaar, Peloquin, & Migliori, 2018). The development of antitubercular drugs started with the accidental discovery of streptomycin, followed by the development of its congener and along with other drugs such as actinomycin, streptothricin, para-aminosalicylic acid, isoniazid, pyrazinamide, D- cycloserine, ethambutol, rifampicin, and rifapentine etc. (Ahamad et al., 2017).
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: As New. Unread book in perfect condition. Bestandsnummer des Verkäufers 49350932
Anzahl: Mehr als 20 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: New. Bestandsnummer des Verkäufers 49350932-n
Anzahl: Mehr als 20 verfügbar
Anbieter: Rarewaves.com USA, London, LONDO, Vereinigtes Königreich
Paperback. Zustand: New. Bestandsnummer des Verkäufers LU-9798230196884
Anzahl: Mehr als 20 verfügbar
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
PAP. Zustand: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Bestandsnummer des Verkäufers L0-9798230196884
Anzahl: Mehr als 20 verfügbar
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Zustand: New. In. Bestandsnummer des Verkäufers ria9798230196884_new
Anzahl: Mehr als 20 verfügbar
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
Zustand: New. Bestandsnummer des Verkäufers 49350932-n
Anzahl: Mehr als 20 verfügbar
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
Zustand: As New. Unread book in perfect condition. Bestandsnummer des Verkäufers 49350932
Anzahl: Mehr als 20 verfügbar
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Quantitative Structure-Activity Relationship 3D Computational Binding and Atomic Dynamics Analysis of Natural and Synthetic Antituberculosis Agents | ¿Ehzade Mehmet | Taschenbuch | Englisch | 2024 | Independent Publisher | EAN 9798230196884 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. Bestandsnummer des Verkäufers 130610519
Anzahl: 5 verfügbar
Anbieter: Rarewaves.com UK, London, Vereinigtes Königreich
Paperback. Zustand: New. Bestandsnummer des Verkäufers LU-9798230196884
Anzahl: Mehr als 20 verfügbar